非布司他效果好吗？

It is a new type of selective non-purine xanthine oxidase (XO) inhibitor, used for patients with gout and hyperuricemia. Gout is a disease caused by disorders of purine metabolism. Generally speaking, in addition to the common hyperuricemia, there are also gouty acute arthritis, tophi deposition, tophi chronic arthritis, joint deformities, nephritis, and uric acid kidney stones. Hyperuricemia often refers to the situation where patients have fasting blood uric acid levels that are higher than normal under a normal purine diet. Patients may be asymptomatic, or may have conditions such as arthritis, gout, and high blood pressure. Febuxostat is indicated for the long-term treatment of hyperuricemia in patients with gout. Not recommended for use in asymptomatic hyperuricemia. There are no studies on the use of febuxostat in patients with secondary hyperuricemia (including organ transplant recipients), so febuxostat is not recommended in patients with massively elevated urate levels (e.g., malignant disease, Lesch-Nyhan syndrome). 

Febuxostat is a selective inhibitor of non-purine xanthine oxidase/xanthine dehydrogenase. In the 2012 American College of Rheumatology Gout Guidelines, febuxostat is recommended as a Class A recommendation for drug treatment of patients with hyperuricemia and gout, which is also the first-line option. In June 2013, China's State Food and Drug Administration approved febuxostat for marketing in China. Is febuxostat effective?

A clinical trial summarized the clinical data of 40 gout patients admitted to the Department of Endocrinology of the Affiliated Hospital of Zunyi Medical College from January 2016 to December 2017. All case data were continuous and complete. According to the medication status of the patients, they were divided into febuxostat group and allopurinol group, with 20 cases in each group. Patients in the febuxostat group took febuxostat tablets orally, and patients in the allopurinol group took orally allopurinol. The serum uric acid levels, gout symptom improvement, post-treatment clinical effects and adverse reactions of the two groups of patients before and after treatment were observed. Results When comparing the serum uric acid levels of the two groups of patients before treatment, there was no statistically significant difference (P>0.05); after treatment, the serum uric acid level of the patients in the febuxostat group [(372.55±90.80) μmol/L] was lower than that of the allopurinol group [(413.25±141.31) μmol/L], and the difference was statistically significant (P<0.05). The serum uric acid compliance rate (55.0%) and symptom improvement rate (95.0%) of patients in the febuxostat group were higher than those in the allopurinol group (35.0%, 85.0%), and the differences were statistically significant (P<0.05). The incidence of adverse reactions in the febuxostat group (20.0%) was lower than that in the allopurinol group (30.0%), and the difference was statistically significant (P<0.05). The conclusion shows that the efficacy and safety of febuxostat in the treatment of gout are more advantageous than allopurinol, and it is worthy of clinical promotion and application. 

Currently, there are three main clinical drugs for the treatment of gout (uric acid-lowering): allopurinol, febuxostat, and benzbromarone. Febuxostat is effective in treating gout. Therefore, many patients tend to choose acid-lowering drugs for gout.